Holen Sie sich die Stockscreener-App
78.16
0.38%
-0.78
Schlusskurs vom Vortag:
$78.94
Offen:
$79.1
24-Stunden-Volumen:
224.70K
Relative Volume:
0.59
Marktkapitalisierung:
$1.77B
Einnahmen:
$747.40M
Nettoeinkommen (Verlust:
$-12.60M
KGV:
-101.68
EPS:
-0.7687
Netto-Cashflow:
$105.18M
1W Leistung:
-4.57%
1M Leistung:
-4.24%
6M Leistung:
+20.58%
1J Leistung:
+41.85%
1-Tages-Spanne:
$78.08
$80.28
1-Wochen-Bereich:
$78.08
$82.53
52-Wochen-Spanne:
$52.73
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
78.77 | 1.77B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
124.58 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.01 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.77 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
488.66 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Revenue per share of ANI Pharmaceuticals, Inc. – MUN:BSFA - TradingView — Track All Markets
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Globe and Mail
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally - Yahoo Finance
ANI Pharma stock pullback tied to Cortrophin guidance uncertainty - Investing.com
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling - MarketBeat
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
Will ANI Pharmaceuticals Inc. stock attract ESG investorsMarket Trend Summary & AI Powered Market Entry Ideas - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $133,652.80 in Stock - MarketBeat
ANI Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
VP Davis Sells 1,622 ($133.7K) Of ANI Pharmaceuticals Inc [ANIP] - TradingView — Track All Markets
How ANI Pharmaceuticals Inc. stock reacts to global recession fearsMarket Growth Review & Reliable Price Breakout Signals - DonanımHaber
Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Can ANI Pharmaceuticals Inc. stock rebound after recent weaknessQuarterly Trade Review & Daily Oversold Bounce Ideas - DonanımHaber
Is ANI Pharmaceuticals Inc. stock trading at a premium valuationWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Recap & Safe Capital Growth Tips - Улправда
ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum - Sahm
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Why ANI Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Finviz
Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? - Yahoo Finance
How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Ranger Investment Management L.P. Reduces Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Implied volatility surging for ANI Pharmaceuticals stock options - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $32,928.00 in Stock - MarketBeat
ANI Pharmaceuticals Senior VP Meredith Cook Sells 400 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (ANIP) officer Meredith Cook sells 400 shares via 10b5-1 plan - Stock Titan
ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim - MSN
ANI Pharmaceuticals (ANIP): Assessing Valuation After a Strong Year and Recent Share Price Pullback - Sahm
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? - MSN
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Nasdaq
ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares - MSN
ANI Pharmaceuticals Director Sold $146K In Company Stock - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock - MarketBeat
ANI Pharmaceuticals Director Sells 1,800 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target - marketscreener.com
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed - MSN
ANI Pharmaceuticals (ANIP): Has the Recent Share Price Pullback Created a Valuation Opportunity? - Yahoo Finance
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by JPMorgan Chase & Co. - MarketBeat
Kennedy Capital Management LLC Reduces Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Governance Shake-Up And FutureVision Launch – Learn Why - Sahm
Is ANI Pharmaceuticals Inc. (BSFA) stock a buy for dividend portfoliosPortfolio Performance Report & Low Drawdown Investment Strategies - Newser
ANI Pharmaceuticals (ANIP): Valuation Check After Governance Shake-Up and New Rare Disease Strategy Moves - Sahm
Sio Capital Management LLC Buys 25,625 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.42%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):